1. Introduction {#sec1}
===============

Inflammatory bowel diseases (IBD), including Crohn\'s disease (CD) and ulcerative colitis (UC), are chronic relapsing and remitting diseases, principally appearing in young adults, with peak onset between the ages of 15 and 30 years \[[@bib1],[@bib2]\]. They are prominent in most developed countries, but it is becoming a global health problem as rising incidence is being observed in the developing world \[[@bib3]\]. Incidence ranges in the United States (US) from approximately 2 to 15 cases per 100,000 person-years and rising for both forms with an estimated prevalence of 3.1 million \[[@bib4], [@bib5], [@bib6]\]. Both types of IBD are clinically characterized by chronic disease courses, variability in disease severity and diversity in clinical manifestations including abdominal pain, diarrhea, hematochezia, weight loss, profound fatigue and frequent occurrence of serious intestinal and systemic disease complications, often leading to surgery and irreversible bowel damage. Consequently, IBD has a major impact on quality of life \[[@bib7],[@bib8]\]. Disability attributed to IBD further increases the economic burden associated with these diseases, especially when it leads to partial or total unemployment in young people \[[@bib9]\].

2. Study rationale {#sec2}
==================

Basic research in IBD during the last few years has made significant advances in unveiling genetic loci of susceptibility, \[[@bib10],[@bib11]\] revealing fundamental insights into enteric microbiota structures and their interaction with the innate and adaptive immune systems, \[[@bib12]\] as well as discovering novel functions for and the regulation of previously recognized innate immune cells \[[@bib13]\]. Additional research efforts have been initiated to predict treatment outcome, \[[@bib14],[@bib15]\] and define risk stratification for disease progression in addition to shedding light on potential environmental triggers and their role in initiating post-infectious functional gastrointestinal disorders such as irritable bowel syndrome and IBD \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\].

Despite such achievements in improving the understanding of IBD, and in part due to such advancements, several challenges and opportunities in IBD research remain \[[@bib21]\]. These include: (1) identifying IBD patient subsets using 'omics' to predict aggressiveness of disease, complications, and response to treatment; understanding how environmental factors enhance the risk of IBD; (2) determining which environmental triggers initiate, perpetuate, and/or reactivate disease; and (3) exploration of the reciprocal interactions and functional pathways that lead to homeostasis versus inflammation with an ultimate goal of identifying novel disease interception strategies. The concept of disease interception from chronic immune-associated diseases is an emerging paradigm in chronic disease management where at-risk individuals are identified in a pre-disease state, or the window of time preceding clinical diagnosis and symptoms during which pathological molecular changes can be detected, and interventions can be targeted to prevent the overt irreversible damage that are associated with the disease process \[[@bib22]\]. Overcoming these recognized challenges requires resources and unique settings whereby serial biospecimens can be obtained from incident IBD patients and in which data and biospecimens are available before disease onset and following treatment.

US military personnel constitute a large cohort of young healthy people particularly affected by IBD \[[@bib19],[@bib23]\]. Unique to this population is an integrated database which links medical, deployment, and other exposure data, in addition to a serum repository which includes pre-disease and interval serum samples that are collected as part of a long-standing and ongoing HIV surveillance program \[[@bib24]\]. Such a setting provides an opportunity to implement a systems proteomic approach to address critical discovery and translational research gaps in a well-characterized population. Coupled with the availability of this unique population data and sample resource, scientific and technologic innovation in recent years has led to high-throughput methodologies exploring proteomic measurements in complex biological systems \[[@bib25]\]. As a consequence, primary discovery endeavors have been built upon and expanded beyond the reductionist approach to the \"holistic\" approach of comprehensively examining the globally interacting elements of biological systems \[[@bib26]\]. The development of this systems approach has become an impetus for research by which large amounts of data are amassed, analyzed, and applied to complex questions of biology that were previously unsolvable. While another IBD pre-disease cohort study has initiated, \[[@bib27]\] it is among genetically high risk individuals (first-degree relatives), and the population in our study represents an opportunity to understand disease processes and biomarkers of risk in a broader, more general population. However, there are some potential limitations given the demographics of this study population.

Thus, the alignment of emerging technologies and the unique data and specimen repository, led to a multinational, academic, industry and governmental partnership entitled "[PR]{.ul}oteomic [E]{.ul}valuation and [D]{.ul}iscovery in an [I]{.ul}BD [C]{.ul}ohort of [T]{.ul}ri-service [S]{.ul}ubjects (PREDICTS)" study to join resources and expertise on which novel discovery and translational research could be built. Furthermore, this partnership was built with the understanding that it represents a unique resource from which others, outside the founding partnership, could benefit and thus the study and opportunity is further described.

3. Cohort desciption {#sec3}
====================

3.1. Study design and participants {#sec3.1}
----------------------------------

This is a nested case-control study of subjects with incident IBD (UC and CD). Two-thousand IBD cases (1000 each with CD or UC) and 500 healthy controls were identified from the Defense Medical Surveillance System (DMSS). This is the main data repository for all US armed forces and contains relevant data from just over 10 million members having served in the armed forces since 1990, documenting their military and medical experiences throughout their career \[[@bib28],[@bib29]\]. Subjects included in this study were active duty US military personnel. Our data (extracted from the DMSS) are limited to the years 1998--2013 (limited to 1998--2011 for CD).

3.2. Case selection {#sec3.2}
-------------------

All selected cases had two or more medical encounters with an ICD-9 code for CD \[555.0, 555.1 and 555.9 (including all subgroup codes)\] or UC \[556 (including all subgroup codes)\] and available serum from the time of IBD diagnosis (±1 year) and from the preceding sampling points as per [Fig. 1](#fig1){ref-type="fig"}. Given that more than 1000 CD and UC cases were present in the database, we created an algorithm for case selection based on criteria as follows:1)≥ 2 medical encounters with an ICD-9 code for IBD;2)Available serum from the time of IBD diagnosis (±1 year) and from the preceding sampling points for that subject, 2, 4 and 6 + years before;3)≥ 1 medical encounters with a CPT code (45330-4, 45338, 45378, 45379, 45382, 45384, 45385) for lower gastrointestinal endoscopic procedure preceding ≥ 1 medical encounter with an ICD-9 code for IBD; and4)Lack of medical encounters with an ICD-9 code for alternative form of IBD (e.g. if UC case, minimizing CD code visits)a.No medical encounters with alternative IBD ICD-9 codeb.≤ 2 medical encounters with alternative IBD ICD-9 codeFig. 1Serum Sample Selection concurrent with and prior to IBD diagnosis for PREDICTS subjects.**Legend:** Sample A was the first sample available following the initial medical encounter in which an IBD diagnosis was made. In the absence of this sample, the last sample prior to that medical encounter was selected. Samples B and C represent the serum samples stored from the three preceding biennial (e.g. every two years) HIV screening test. Sample D represented the earliest serum sample available in the repository.Fig. 1

At a minimum, all subjects met criteria 1 and 2 above; however, preferential inclusion was given to subjects meeting criteria 3 and 4. The following algorithm outlines the order in which subjects were selected: 1,2,3,4a \>1,2,3,4b \> 1,2,3 \> 1,2.

3.3. Control selection {#sec3.3}
----------------------

Controls were matched on age, gender, race and timing of Sample A (±1 year) to UC cases. Control subjects were required to have no medical encounter evidence of Crohn\'s Disease \[ICD9-CM: 555.0, 555.1, 555.9 (including all subgroup codes)\], ulcerative colitis \[ICD9-CM: 556 (including all subgroup codes)\], rheumatoid arthritis (ICD9-CM: 714.0), celiac disease (ICD9-CM: 579.0) or colorectal cancer (ICD9-CM: 153.0--154.1).

3.4. Clinical and covariate data {#sec3.4}
--------------------------------

Subjects for this study were identified from the DMSS from 1998 to 2013 (CD cases limited to 1998--2011). Medical encounter data were obtained from ambulatory and inpatient claims data for care obtained within the Military Health Services and the Tri-Service Reportable Events System data ([Table 1](#tbl1){ref-type="table"}). Demographic information including age, gender, race, education level, rank, marital status, and branch of service were obtained from personnel data records. Deployment data were derived from deployment rosters and deployment health assessments. All medical encounters with an IBD diagnosis at any diagnostic position were obtained from Armed Forces Health Surveillance Branch (AFHSB). Medical encounters associated with a procedural code for colonoscopy (CPT codes shown in [Table 1](#tbl1){ref-type="table"}) were also obtained. Infectious gastroenteritis (IGE), determined from ICD-9 codes for specific bacterial and viral pathogens, were also obtained ([Table 1](#tbl1){ref-type="table"}). All ICD-9 and CPT codes assigned in IBD-related medical encounters were also available, and allowed assessment of surgery rates, or other disease-associated complications. In an effort to assess exposures unique to this military population, deployment history was obtained to include the name of the operational deployment, duration of deployment and timing of deployment relative to disease onset. No information on smoking status, family history, medications, pathological results, radiographic studies, and/or clinical laboratory results was available.Table 1List of variables available for study.Table 1All IBD Visits \[CD - ICD9-CM: 555.0, 555.1 and 555.9 (including all subgroup codes) or UC \[ICD9-CM: 556 (including all subgroup codes)\] medical encounters Date of medical encounter All ICD-9 codes affiliated with medical encounter Visit type (e.g., inpatient or outpatient)**All IBS (**ICD9-CM: 564.1**), or IGE (**ICD9-CM: 001 \[all subgroups\], 003.0, 003.9, 004 \[all subgroups\], 008.0, 008.43, 008.44, 008.8, 005.4, 008.47, 008.49, 008.5, 009.0--3, 005.8, 005.9, 006.0, 006.1, 006.2, 006.9, 007 \[all subgroups\], 008.6 \[all subgroups\]) **medical encounters prior and subsequent to initial IBD diagnosis** Date of medical encounter All ICD-9 codes affiliated with medical encounter Visit type (e.g., inpatient or outpatient)**All medical encounters in which a procedural code for colonoscopy was utilized** Date of medical encounter All ICD-9 and CPT codes affiliated with medical encounter Visit type (e.g., inpatient or outpatient)**All operational deployments** Date of deployment Duration of deployment Operation**Demographic Variables** Year of birth Gender Race Education level Military Rank Marital status Branch of service

3.5. Serum sampling {#sec3.5}
-------------------

For each IBD case and healthy control (HC), up to four serum samples were obtained from the DoD serum repository. Sample A was the first sample available following the initial medical encounter in which an IBD diagnosis was made ([Fig. 1](#fig1){ref-type="fig"}). In the absence of this sample, the last sample prior to that medical encounter was selected. Samples B and C represent the serum samples stored from the three preceding biennial (e.g. every two years) HIV screening test. In the absence of available serum, efforts were made to approximate two year intervals between serum samples. Sample A from HC subjects (frequency matched on age, race, gender and time) were matched to Sample A from UC cases based on year of collection (±1 year). Samples B and C represented samples obtained approximately two and four years prior to Sample A, respectively, without specific year-matching to the case samples. Sample D represented the earliest serum sample available in the repository. Serum samples were obtained in aliquots of 0.5 mL (from original 2.5 mL patient sample) for each subject and timepoint and labeled with a unique identifier which described both individual and sample timepoint. Serum at the DoD Serum Repository was archived at −30 °C, and upon transfer to the Naval Medical Research Center is held at −80 °C with continuous monitoring.

3.6. Biorepository description {#sec3.6}
------------------------------

A centralized repository was established to collect, process, store, and distribute biospecimens and data to support scientific investigation. Accessions of samples were recorded as having arrived and maintained by unique sample ID. Upon thawing and sub-aliquoting a laboratory information management system is used to barcode each 'daughter' sample which links to the parent sample. Information on sample data and arrival are maintained. Parallel to the sample accession and archive system, data on subjects (e.g. demographics, diagnosis, deployments, and procedures) are received, curated and housed in a limited access central repository which maintains data integrity and links to specimen identification.

Processing of samples (subaliquoting) was initially performed manually to minimize repetitive freeze-thaws and subsequently transitioned to an automated process to minimize variations in sample handling. For each serum testing request and analysis plan, the parent serum is thawed once and multiple daughter aliquots are made which meet the volume requirement of the planned testing as well as anticipating future testing of retained daughter aliquots. Daughter samples are either immediately shipped if testing is to commence upon first thaw, or refrozen and sent to partner laboratories. Daughter samples are contained in bar-code labeled cryovials with a desiccation proof seal. No additives are used in the aliquoting and storage processes.

All samples are held at the Naval Medical Research Center prior to being requested via a distribution request. The inventory system is composed of sample holding boxes and the boxes are stored in monitored freezers at −80 °C. Accompanying data associated with samples are archived in a master database from which analytic subsets are generated. The process of requesting specimens and data from the repository are later described.

3.7. Sample size and statistical analysis {#sec3.7}
-----------------------------------------

This study was designed to evaluate up to 1000 cases each of UC and CD, and 500 controls \[age-, gender-, race -and time-frequency matched to the UC cases\] with considerations of power to detect a significant difference in a single serologic marker being predicated on the seroprevalence of that marker in cases and controls through utilization of a variety of statistical techniques including traditional bivariate and multivariate analysis, as well as cluster analysis, ordination methods, and machine learning techniques. Given the exploratory nature of this study, we estimated that the proposed sample size would have over an 80% power to identify a significant difference in the presence of a single marker in cases and controls if the biomarker is present in as few as 10% of the cases with a seropositivity rate twice as in the control subjects (2-group continuity-adjusted chi-square test with two-sided *alpha* = 0.05). Additionally, among IBD cases, a single group repeated measures analysis of variance (*alpha* = 0.05) would have an 80% power to detect a change in specific parameter characterized by an effect size (an index of the separation expected between the observed means based on mean variance within and across subjects) of 0.0027. It was further anticipated that adjustments for multiple comparisons will be needed to control the Type I error rate which may yield a lower overall statistical power. Given the utilization of network analyses to maximize the probability of identifying statistical data patterns, it is anticipated that this study is powered adequately to identify significant differences in serum profiles across the study populations assuming there are in fact differences in the studied groups. Precise statistical methods and models to be used will be unique for each research objective; however, a general strategy has been proposed to include testing and evaluation on parallel subsets with validation on an independent subset.

3.8. Baseline description of the cohort {#sec3.8}
---------------------------------------

The demographics of the PREDICTS population are outlined in [Table 2](#tbl2){ref-type="table"} and, in general, are reflective of the active duty US military population. Specifically, the majority of IBD subjects and healthy controls are male (82.5% and 92.0%, respectively) with no significant differences in IBD pathotypes (p = 0.7); however, control subjects are more predominantly male (p \< 0.001). There are no significant differences in the age distribution of subjects (p = 0.5) with 84.8% under the age of 40 across all groups. As expected, less than 25% of the subjects are officers with a slightly higher proportion of enlisted personnel in the CD (82.1%) compared to UC (75.4%; p \< 0.001) or HC cohorts (77.6%; p = 0.04). Approximately 70% of the CD subjects are classified as white, which is lower than UC (78.1%; p \< 0.001) or HC subjects (82.8%; p \< 0.001). The majority of subjects across all disease states had at least one operational deployment prior to the initial disease diagnosis (CD or UC) or matching HC. As shown in [Fig. 3](#fig3){ref-type="fig"}, incident cases (and HCs) were identified across the entire study period.Table 2Demographics of PREDICTS study population.Table 2Crohn\'s diseaseUlcerative colitisHealthy controlsN%N%N%**Gender** Male82282.2%82882.8%46092.0% Female17817.8%17217.2%408.0%**Age** 20-2944544.5%42742.7%21042.0% 30-3940932.8%41135.5%21835.5% 40-4913514.5%14716.7%7115.8% \>=50111.2%151.6%10.2%**Education** High school (or equivalent)69169.1%58658.6%32464.8% Some college929.2%13413.4%5210.4% College12012.0%18118.1%7715.4% Advanced degree757.5%757.5%367.2% Unknown222.2%242.4%112.2%**Marital status** Married77na71371.3%36973.8% Single/Other23na28728.7%13126.2%**Military Rank** Jr. Enlisted18518.5%14014.0%7014.0% Sr. Enlisted63663.6%61461.4%31863.6% Officer17917.9%24624.6%11222.4%**Branch of Service** Armynana32432.4%16132.2% Air Forcenana26326.3%11422.8% Marinesnana10910.9%5210.4% Navy/Coast Guardnana30430.4%17334.6%**Race/Ethnicity** White69669.6%78178.1%41482.8% Black15615.6%17117.1%7114.2% Other14814.8%484.8%153.0%**Deployments** Deployed62869.1%73877.1%39081.9% Not deployed37233.1%26225.0%11021.4%[^3]

4. Findings to date {#sec4}
===================

As shown in [Fig. 4](#fig4){ref-type="fig"}, disease-associated samples from CD and UC subjects were obtained a median of 145 (interquartile range (IQR): 16, 311) and 3 (IQR: −100, 230) days from the incident IBD diagnosis, respectively. All control samples were obtained at the time of censoring. Antecedent samples for CD were obtained at a median of 1.6 (IQR: 0.8, 2.0), 4.0, (3.6, 6.1) and 6.0 (5.6, 8.0) years prior to the initial medical encounter with the CD-associated ICD-CM encounter. Similar samples for the UC subjects were obtained at a median of 2.0 (IQR: 1.6, 2.3), 4.0, (IQR: 3.6, 4.4) and 9.5 (IQR: 6.7, 13.3) years prior to the incident diagnosis.

As shown in [Table 3](#tbl3){ref-type="table"}, among the CD cases, just over 50% of the subjects had evidence within the DMSS of being seen in a gastroenterology clinic concurrent with any CD-associated medical encounter. Gastroenterologist associated visits obtained outside of the Military Health System, which occurs commonly in areas that do not have specialist availability, lacked visit specification in the database. This proportion was significantly higher in the UC cases (%, p \< 0.001).73.4%). Depending on IBD subtype, 11--15% of subjects had at least one inpatient IBD-related medical encounter (CD: 36.0%, UC: 26.6%) with a median of one inpatient encounter for each admitted subject. Procedural and ICD-9-CM-based codes for endoscopy highlight a significant difference in the prevalence of these procedures being documented in the DMSS with a significantly higher proportion of UC subjects (68.1%, p \< 0.001)) with at least one concurrent endoscopy compared to CD subjects (36.8%). Throughout the medical encounter history, CD and UC subjects often received multiple visit-associated sub-codes. While the most common CD sub-code was 'regional enteritis, unspecified site' documented in just over 85% of subjects, small and large intestine sub-codes were also documented in 42.5% and 41.8% of subjects, respectively. Additionally, a small proportion of CD subjects received UC co-diagnoses during their IBD workup. Similarly to CD, UC subjects received a spectrum of UC-specific sub-codes, the most common being 'ulcerative colitis, unspecified' documented in 87.3% of the UC cases and identified in a median of 7 (IQR: 3, 16) separate encounters for each subject with that sub-code. Other sub-codes such as 'universal ulcerative colitis' (40.1%), 'ulcerative proctitis' (30.6%) and 'left-sided ulcerative colitis' (24.6%) were also common. Additional data to assist in classification of standard phenotype of disease severity based on disease location and behavior, and history of surgery are also available in the repository (data not shown).Table 3Additional information related to medical CD- or UC-associated medical encounters.Table 3N (%) with CD/UC-associated medical encountersMedian (IQR) visits per subjectCDUCCDUCGastroenterology clinic555 (55.5)734 (73.4)4 (2, 9)5 (2, 9)Inpatient encounter360 (36.0)266 (26.6)1 (1, 2)1 (1, 2)Endoscopy368 (36.8)681 (68.1)1 (1, 2)2 (1, 2)Regional enteritis, small intestine425 (42.5)0 (0.0)3 (1, 6)--Regional enteritis, large intestine418 (41.8)1 (0.1)2 (1, 5)1 (1, 1)Regional enteritis, small/large intestine218 (21.8)0 (0.0)2 (1, 4)--Regional enteritis, unspecified site866 (86.6)2 (0.2)6 (2, 14)1 (1, 1)Ulcerative enterocolitis0 (0.0)0 (0.0)----Ulcerative ileocolitis2 (0.2)41 (4.1)2 (1, 2)1 (1, 2)Ulcerative proctitis6 (0.6)306 (30.6)2 (1, 2)3 (1, 6)Ulcerative proctosigmoiditis3 (0.3)165 (16.5)1 (1, 1)2 (1, 4)Pseudopolyposis colon14 (1.4)34 (3.4)1 (1, 1)1 (1, 2)Left-sided ulcerative colitis1 (0.1)246 (24.6)1 (1, 1)2 (1, 4)Universal ulcerative colitis13 (1.3)401 (40.1)1 (1, 2)3 (1, 7)Other ulcerative colitis5 (0.5)281 (28.1)1 (1, 1)2 (1, 3)Ulcerative colitis, unspecified33 (3.3)873 (87.3)1 (1, 1)7 (3, 16)Intestinal resection[a](#tbl3fna){ref-type="table-fn"}70 (7.0)54 (5.4)2 (1, 4)3 (2, 9)Infusion procedure (biological)[b](#tbl3fnb){ref-type="table-fn"}25 (2.5)0 (0.0)1 (1, 1)--[^4][^5]

In addition to the IBD-related medical encounters, subjects received ICD-9-CM codes associated with other diseases concurrent with all pre- and post-diagnosis IBD-related medical encounters ([Table 4](#tbl4){ref-type="table"}). The most common co-diagnoses were diseases of the digestive system (occurring in 58.9% of the CD cases and 63.0% of the UC cases) and symptoms, signs and ill-defined conditions (occurring in 53.9% of CD cases and 55.4% of the UC cases) with no significant difference in the proportion of cases (p = 0.5 and 0.06, respectively). ICD-9-CM codes for diseases of the digestive system were assigned on a total of over 2500 (CD: 2714; UC: 2555) separate IBD-related encounters for a median of three encounters per CD case (IQR: 1, 6) and two for each UC case (IQR: 1, 5). Diseases of the musculoskeletal system and connective tissue were also common among cases (CD: 25.7%, UC: 30.5%) with a median of two visits per case. Diseases of the circulatory system were more common among UC cases (25.2%) than CD cases (17.6%), as were endocrine, nutritional and metabolic diseases and immunity (p \< 0.001 and p = 0.002, respectively). Among the HC subjects, the most commonly identify medical encounters were similar to the co-diagnosed conditions among the IBD cases with symptoms, signs and ill-defined conditions being most common (44.2%) followed by mental disorders (28.4%) and diseases of the digestive system (17.6%). The median IBD related medical follow-up following incident diagnosis was 373 days (IQR: 151, 977) and 852 days (IQR: 350, 1967) for CD and UC, respectively.Table 4ICD-9-CM codes corresponding with IBD-related medical encounters and all HC-associated encounters.Table 4ICD-9-CM descriptionICD-9-CM codeNumber (%) of subjects with co-DiagnosesTotal number, median (IQR) of separate medical encountersCDUCHCCDUCHCInfectious and parasitic diseases001--139120 (12.0)145 (14.5)61 (12.2)2451 (1,2)3401 (1, 3)881 (1, 2)Neoplasms140--23977 (7.7)158 (15.8)26 (5.2)1231 (1, 2)2961 (1, 2)811 (1, 2)Endocrine, nutritional and metabolic diseases and immunity disorders240--279202 (20.2)263 (26.3)55 (11.0)4822 (1, 3)8442 (1, 4)991 (1, 2)Diseases of the blood and blood forming organs280--289155 (15.5)206 (20.6)29 (5.8)4822 (1, 4)7452 (1, 4)1202 (1, 4)Mental disorders290--319207 (20.7)199 (19.9)142 (28.4)6192 (1, 4)6542 (1, 3)8133 (1, 6)Diseases of the nervous system320--35999 (9.9)119 (11.9)19 (3.8)2231 (1, 2)2871 (1, 3)221 (1, 1)Diseases of the sense organs360--38947 (4.7)88 (8.8)11 (2.2)691 (1, 2)1441 (1, 1)141 (1, 2)Diseases of the circulatory system390--459176 (17.6)252 (25.2)40 (8.0)3671 (1, 2)7482 (1, 3)651 (1, 2)Diseases of the respiratory system460--519117 (11.7)154 (15.4)55 (11.0)2191 (1, 2)3001 (1, 2)1181 (1, 2)Diseases of the digestive system520--579589 (58.9)[a](#tbl4fna){ref-type="table-fn"}630 (63.0)[b](#tbl4fnb){ref-type="table-fn"}88 (17.6)2714[a](#tbl4fna){ref-type="table-fn"}3 (1,6)2555[b](#tbl4fnb){ref-type="table-fn"}2 (1, 5)1981 (1, 2)Diseases of the genitourinary system580--62997 (9.7)96 (9.6)39 (7.8)2071 (1, 2)1721 (1, 2)691 (1, 2)Complications of pregnancy, childbirth and the puerperium630--67917 (1.7)23 (2.3)10 (2.0)1256 (4, 10)1633 (2, 6)303 (2, 4)Diseases of the skin and subcutaneous tissue680--709136 (13.6)155 (15.5)19 (3.8)2331 (1, 2)2981 (1, 2)281 (1, 2)Diseases of the musculoskeletal system and connective tissue710--739257 (25.7)305 (30.5)73 (14.6)7002 (1, 3)9932 (1, 4)1881 (1, 3)Congenital anomalies740--75930 (3.0)13 (1.3)5 (1.0)451 (1, 2)181 (1, 2)81 (1, 2)Certain conditions originating in the perinatal period760--7792 (0.2)1 (0.1)0 (0.0)21 (1, 1)8 (-, -)0 (-, -)Symptoms, signs and ill-defined conditions780--799539 (53.9)554 (55.4)221 (44.2)22152 (1, 5)22982 (1, 5)8392 (1, 4)Injury and poisoning800--999119 (11.9)110 (11.0)51 (10.2)2521 (1, 2)2191 (1, 2)1081 (1, 2)[^6][^7]

5. Discussion {#sec5}
=============

Herein we have described a large cohort of active duty US military personnel with incident Crohn\'s disease or ulcerative colitis along with matched healthy control subjects in which serum samples have been periodically collected prior to and immediately after IBD onset. This cohort study, called PREDICTS, is designed as a platform study that may revolutionize our understanding of IBD pathoetiology and facilitate movement toward individualized medicine and disease risk prediction and ultimately prevention \[[@bib22],[@bib30],[@bib31]\]. Ongoing serologic assays include those focused on unique proteomic markers, serologic evidence of infectious exposures, cytokine profiles and responses to commensal intestinal microbiota will serve to generate new hypotheses for future *in* and *ex vivo* IBD research \[[@bib16]\]. We recognize that other cohort studies exist including the Nurses Health Study I and II, and the GEM (Genetics, Environmental, Microbial) Project that promise to provide unique opportunities to address current research gaps. However, the PREDICTS study is unique given the availability of multiple samples in the pre-clinical period and the opportunity this affords in discerning factors that are associated with initial triggers and progression of subclinical immuno-inflammatory processes, before overt disease has been established \[[@bib22],[@bib32]\].

This cohort of IBD patients represents a well-characterized group of subjects whose initial sample collections were obtained during periods of time in which the subjects were sufficiently healthy to actively serve in the US military. While these outcomes have not been validated by chart review, a significant proportion of both UC and CD cases have 'confirmatory' medical encounter data that provide confidence in the diagnoses, such as codes associated with gastroenterology specialists visits and endoscopic procedures. It is important to note that the absence of these data does not reduce the likelihood of these being actual IBD cases. The primary reasons for missing 'confirmatory' data are likely multifactorial, and may include the absence of an available Department of Defense specialty clinic at the duty site and subsequent civilian care (specialist and endoscopy procedures) received which are not recorded into the DMSS, or simply incomplete or inaccurate records.

We also fully recognize that an ideal study of this type would involve multiple specimen types including genetic, tissue biopsy, fecal and whole blood specimens in a prospectively designed study where detailed diagnostic, treatment, and exposure data would be collected. Such studies are underway and promise to yield high quality data on which similar hypotheses could be tested \[[@bib33]\]. The limitation of this study to serum is recognized but does not preclude important and rigorous research possibilities. While genetics clearly play an important role in IBD, it only explains a proportion of IBD risk \[[@bib34]\]. Poor correlation between the regulation of transcripts and actual protein quantities may confound associations between genetic polymorphisms disease likely due to the fact that genomic analysis does not account for post-translational processes such as protein modifications and protein degradation or epigenetic changes. Therefore, methods employed in the disease biomarker process have expanded to include proteomics which has allowed for interrogation of these systems indirectly through the serum compartment \[[@bib35]\]. In addition, the readily accessible sample type (e.g., blood draw) may have practical considerations in the future development of clinically applicable screening and evaluation tools. In addition to lack of complementary specimen types, this study is limited by available medical and demographic data which are obtainable in the DMSS as well as the inability to link with medical encounter data upon discharge from Active Duty. Clinical laboratory data, endoscopic and histological data, pharmacy data, as well as smoking status and other behavioral risk factor information are unavailable. While other prospective studies of active duty military populations have included post-discharge follow-up data, the de-identified nature of PREDICTS precludes linking with those ongoing studies, and does not allow for prospectively following participants who may be beneficiaries in the Veteran Affairs system.

Despite these limitations, the number of clinical cases, accessible clinical and exposure data in the data archive, as well as serial serum time points provide a robust platform to inform relevant gaps in our knowledge and understanding of IBD. At present, one study has been published from the PREDICTS study in which antimicrobial biomarkers tested many years prior to disease diagnosis were found to predict complicated disease phenotype at clinical presentation \[[@bib16]\]. Efforts are underway to expand these initial findings. In addition, a variety of protein and antibody panels are currently being evaluated to explore additional aims of biomarker prevalence at clinical onset, biomarker conversion associated with disease onset, enteric infection and disease/biomarker conversion, novel disease biomarkers and pathogenesis, biomarker results compared to historical populations, demographic and deployment factors and association with disease biomarkers, as well as biomarkers predicting disease progression after diagnosis. The potential value and utility of PREDICTS has yet to be fully revealed, and we hope that through future collaborations, advances in technology, and accumulation of a data set rich in multiple biomarker results, and promises of advances in our understanding of IBD that translate into new solutions and practice changes will be fulfilled. Finally, with this initiative we feel that we have provided a blueprint for the creation of public-private pre-competitive partnerships to investigate disease triggers and lay the foundation for disease interception and prevention.
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